CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Neuroendocrine neoplasms: Evolving and future treatments
Authors
A. Spyroglou Bramis, K. Alexandraki, K.I.
Publication date
1 January 2021
Publisher
Abstract
Neuroendocrine neoplasms (NENs) are relatively rare neoplasms. Most NENs are slowly progressing malignancies with prolonged survival even in the presence of advanced metastatic disease, implying an increased need for additional therapies on failure of those initially administered. However, a subset of NENs may display truly aggressive behavior, often refractory to current chemotherapeutic regimens, underlining the need for more appropriate schemes. Following these unmet needs, new therapies are emerging based on advances of NEN pathogenesis, along with modifications of those previously used to improve their efficacy. Long-acting somatostatin analogs also in above-label doses, molecular and peptide receptor radionuclide targeted treatments, chemotherapy, and immunotherapy are available options, but their appropriate sequence is still to be defined, and the choice of monotherapy or combination therapy should be individualized. Advances in the molecular pathogenesis of NENs and larger prospective studies will shed light on biomolecular tumor markers, suggesting the appropriate sequence of treatment in individual patients. © 2021 Elsevier Lt
Similar works
Full text
Available Versions
Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:lib.uoa.gr:uoadl:3102079
Last time updated on 10/02/2023